P. Husa Et Al. , "C EDGE HEAD 2 HEAD Efficacy and safety of elbasvir grazoprevir versus sofosbuvir pegylated interferon ribavirin PR in treatment naive and prior PR treatment failure subject with chronic HCV GT1 or 4 infection," EASL , 2016
Husa, P. Et Al. 2016. C EDGE HEAD 2 HEAD Efficacy and safety of elbasvir grazoprevir versus sofosbuvir pegylated interferon ribavirin PR in treatment naive and prior PR treatment failure subject with chronic HCV GT1 or 4 infection. EASL .
Husa, P., Jan, s., Urbanek, P., Gerstoft, J., Weis, n., Horvath, g., ... Hunyady, b.(2016). C EDGE HEAD 2 HEAD Efficacy and safety of elbasvir grazoprevir versus sofosbuvir pegylated interferon ribavirin PR in treatment naive and prior PR treatment failure subject with chronic HCV GT1 or 4 infection . EASL
Husa, Petr Et Al. "C EDGE HEAD 2 HEAD Efficacy and safety of elbasvir grazoprevir versus sofosbuvir pegylated interferon ribavirin PR in treatment naive and prior PR treatment failure subject with chronic HCV GT1 or 4 infection," EASL, 2016
Husa, Petr Et Al. "C EDGE HEAD 2 HEAD Efficacy and safety of elbasvir grazoprevir versus sofosbuvir pegylated interferon ribavirin PR in treatment naive and prior PR treatment failure subject with chronic HCV GT1 or 4 infection." EASL , 2016
Husa, P. Et Al. (2016) . "C EDGE HEAD 2 HEAD Efficacy and safety of elbasvir grazoprevir versus sofosbuvir pegylated interferon ribavirin PR in treatment naive and prior PR treatment failure subject with chronic HCV GT1 or 4 infection." EASL .
@conferencepaper{conferencepaper, author={Petr Husa Et Al. }, title={C EDGE HEAD 2 HEAD Efficacy and safety of elbasvir grazoprevir versus sofosbuvir pegylated interferon ribavirin PR in treatment naive and prior PR treatment failure subject with chronic HCV GT1 or 4 infection}, congress name={EASL}, city={}, country={}, year={2016}}